Neotrofin increases heme oxygenase-1 selectively in neurons.
There is evidence that heme oxygenase plays a role in cellular defense against reactive oxygen species and thereby has neuroprotective effects. We examined the interaction of Neotrofin, a cognitive-enhancing and neuroprotective drug, with the heme oxygenase system. In adult rats, both a single administration or seven daily injections of Neotrofin at 10, 30 or 100 mg/kg intraperitoneally increased HO-1 immunoreactivity in neurons of the hippocampal formation and its connections including CA1-4, fornix, septal nuclei, hippocampal commissure, septohippocampal nucleus, fimbria, anteroventral thalamic nucleus, frontal and parietal cortex. Prominent HO-1 staining of neuronal cells in the proximity of blood vessels and circumventricular organs was also observed. Increasing doses of Neotrofin resulted in an increase in the number of neuronal populations expressing HO-1 with 100 mg/kg evoking a widespread neuronal cell response in brain. Quantification by ELISA confirmed that intraperitoneal administration of 100 mg/kg Neotrofin caused a significant increase in HO-1 protein expression in the hippocampus. The increase was evident by 6 h post-injection, peaked at 24 h with a 4-fold increase, and persisted for at least 48 h. Similarly, oral administration of 100 mg/kg Neotrofin produced a 5-fold increase in HO-1 protein 24 h post-administration. The effect of Neotrofin on HO-1 appears to be at the transcriptional level, as suggested by an increase in HO-1 mRNA levels. Neotrofin treatment was also associated with a significant increase in HO-2 mRNA levels in whole brain homogenate. These data may explain the neuroprotective effects of Neotrofin in models of excitotoxic neuronal injury.
Wang
Xiaojun
X
Department of Biochemistry and Biophysics, Box 712, University of Rochester School of Medicine, 601 Elmwood Ave., Rochester, NY 14642, USA.
Hauptmann
Nils
N
Taylor
Eve
E
Foreman
Mark
M
Khawli
Leslie A
LA
Maines
Mahin D
MD
D062365:Aminobenzoates; D000818:Animals; D001921:Brain / Q000201:enzymology*; D006419:Heme Oxygenase (Decyclizing) / Q000187:drug effects / Q000378:metabolism*; D051547:Heme Oxygenase-1; D006624:Hippocampus / Q000201:enzymology; D007042:Hypoxanthines; D007150:Immunohistochemistry; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000201:enzymology*; D018697:Nootropic Agents / Q000494:pharmacology*; D009928:Organ Specificity; D011687:Purines; D017966:Pyramidal Cells / Q000201:enzymology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013788:Thalamus / Q000201:enzymology
D062365:Aminobenzoates; D007042:Hypoxanthines; D018697:Nootropic Agents; D011687:Purines; C086241:4-((3-(1,6-dihyro-6-oxo-9H-purin-9-yl)-1-oxopropyl)amino)benzoic acid; D006419:Heme Oxygenase (Decyclizing); D051547:Heme Oxygenase-1; C105245:heme oxygenase-2